Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Parallel-controlled, Open-label, Multicenter Phase III Clinical Study to Compare the Efficacy and Safety of D-0502 With Fulvestrant in Patients With Previously Treated ER-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer

NCT06954961 is registered in ClinicalTrials.gov with InventisBio Co., Ltd as lead sponsor.

NCT NCT06954961
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06954961 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Parallel-controlled, Open-label, Multicenter Phase III Clinical Study to Compare the Efficacy and Safety of D-0502 With Fulvestrant in Patients With Previously Treated ER-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
Lead sponsor
InventisBio Co., Ltd
Phase
Phase 3
Overall status
Recruiting
Start date
September 15, 2022
Completion date
December 31, 2028
Enrollment
640 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer